* Searle & Co., a subsidiary of St. Louis-based Monsanto Co., andChiron Corp. have signed an agreement to develop and market Searle'stissue factor pathway inhibitor (TFPI) for treatment of thrombotic andinflammatory diseases as well as sepsis.Financial terms were not disclosed. Searle, of Skokie, Ill., and Chiron,of Emeryville, Calif., initially will try to develop TFPI for preventionof coagulation in microvascular surgery. Phase I clinical trials areexpected to begin this year.Searle and Chiron will share equally in research and developmentcosts. Searle will have primary responsibility for marketing and Chironwill manufacture the product.* CytRx Corp., of Norcross, Ga., has begun enrolling patients in aPhase I trial to evaluate its compound, CRL-1336, in the treatment ofdrug-resistant canceru Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., was awarded$80,000 under Phase I of a Small Business Innovation Researchprogram grant by the National Institutes of Health for development ofProScan-A, a diagnostic imaging agent for HIV.* Bio-Technology General Corp., of Iselin, N.J., said that BioLon, aready-to-use syringe containing a 1 percent solution of sodiumhyaluronate for use in ophthalmic surgery procedures, was grantedmarketing approval in France.u HemaSure Inc., of Marlborough, Mass., is collaborating with theSwiss Red Cross to expedite development of HemaSure's LeukoVirFilter, which is designed for use in the viral inactivation of plasma fortransfusion.* Advanced Magnetics Inc., of Cambridge, Mass., acquired themarketing rights to the magnetic resonance imaging contrast agentpreviously sold to Squibb Diagnostics, a division of Bristol-MyersSquibb. Bristol-Myers returned to Advanced Magnetics a warrant forthe purchase of 600,000 shares of stock; Advanced Magnetics will payBristol-Myers $1 million.

(c) 1997 American Health Consultants. All rights reserved.